These data confirm previous studies that PD166285 inhibits both Wee1 and Myt1 whereas Adavosertib inhibits Wee1, but not Myt1 in cancer cells (Wang et al., 2001; Lewis et al., 2019). This evidence concerns the gene MYT1 and cancer.